<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04320602</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN1210-PNH-401</org_study_id>
    <secondary_id>2019-003440-74</secondary_id>
    <nct_id>NCT04320602</nct_id>
  </id_info>
  <brief_title>Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab</brief_title>
  <official_title>Phase 4, Single-Arm Study of Ravulizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Currently Treated With High-Dose Eculizumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to assess the safety, efficacy, pharmacokinetics, and
      pharmacodynamics of ravulizumab in participants who are prescribed and are receiving a higher
      than approved dose of eculizumab to treat paroxysmal nocturnal hemoglobinuria (PNH).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion Of Participants Who Experience Free Complement Component 5 (C5)-associated Breakthrough Hemolysis (BTH)</measure>
    <time_frame>Baseline through Day 351</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion Of Participants Who Experience BTH</measure>
    <time_frame>Baseline through Day 351</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemolysis As Directly Measured By Lactate Dehydrogenase (LDH) Percent Change From Baseline To Day 351</measure>
    <time_frame>Baseline, Day 351</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Of Participants Who Receive A Transfusion</measure>
    <time_frame>Baseline through Day 351</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Of Participants With Stabilized Hemoglobin</measure>
    <time_frame>Baseline through Day 351</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Paroxysmal Nocturnal Hemoglobinuria</condition>
  <arm_group>
    <arm_group_label>Ravulizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive eculizumab during the 3-month Screening Period. Participants will then switch over to and receive weight-based doses of ravulizumab for the duration of the study Treatment Period (351 days).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Participants must have been prescribed and be receiving a stable dose of eculizumab 1200 milligrams (mg) every 2 weeks (q2w) for at least 3 months prior to the Screening Period. During the Screening Period, participants will continue to receive eculizumab 1200 mg q2w.</description>
    <arm_group_label>Ravulizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ravulizumab</intervention_name>
    <description>During the Treatment Period, participants will receive a loading dose of ravulizumab on Day 1, followed by maintenance doses on Day 15 and every 8 weeks, administered by intravenous infusion. Ravulizumab loading and maintenance doses will be based on participants' body weight per approved dose regimen.</description>
    <arm_group_label>Ravulizumab</arm_group_label>
    <other_name>ALXN1210</other_name>
    <other_name>Ultomiris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Documented diagnosis of PNH, confirmed by high-sensitivity flow cytometry evaluation
             of red blood cells and white blood cells, with granulocyte or monocyte clone size of ≥
             5%.

          2. Received 1200 mg eculizumab every 12 to 16 days (every 2 weeks) for at least 3 months
             prior to Screening.

          3. LDH ≤ 2 x upper limit of normal (ULN) according to central laboratory, at Screening.

          4. To reduce the risk of meningococcal infection (Neisseria meningitidis), all
             participants must be vaccinated against meningococcal infections within 3 years prior
             to initiating study drug.

          5. Body weight ≥ 40 kilograms.

        Key Exclusion Criteria:

          1. History of major adverse vascular events within 6 months of Day 1.

          2. History of bone marrow transplantation.

          3. Lymphoma, leukemia, myelodysplastic syndrome, or any malignancy within the past 5
             years except for basal cell or squamous epithelial carcinomas of the skin that have
             been resected with no evidence of metastatic disease for 3 years.

          4. Concomitant use of anticoagulants is prohibited if not on a stable regimen for at
             least 2 weeks prior to Day 1.

          5. Concomitant use of any of the following medications and not on a stable regimen (as
             judged by the Investigator) for the time period indicated prior to Screening:

               -  Erythropoietin or immunosuppressants for at least 8 weeks

               -  Systemic corticosteroids for at least 4 weeks

               -  Vitamin K antagonists (for example, warfarin) with a stable international
                  normalized ratio level for at least 4 weeks

               -  Iron supplements or folic acid for 4 weeks

          6. Live vaccine(s) within 1 month prior to Screening or plans to receive such vaccines
             during the study.

          7. More than 1 LDH value &gt; 2 × ULN within the 6 months prior to Day 1.

          8. Platelet count &lt; 30,000/cubic millimeter (30 × 10^9/Liter [L]) at Screening.

          9. Absolute neutrophil count &lt; 500/microliter (0.5 × 10^9/L) at Screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals Inc.</last_name>
    <phone>855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>March 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2020</study_first_posted>
  <last_update_submitted>June 18, 2020</last_update_submitted>
  <last_update_submitted_qc>June 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal Nocturnal Hemoglobinuria</keyword>
  <keyword>PNH</keyword>
  <keyword>Ravulizumab</keyword>
  <keyword>Ultomiris</keyword>
  <keyword>Eculizumab</keyword>
  <keyword>Soliris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemoglobinuria</mesh_term>
    <mesh_term>Hemoglobinuria, Paroxysmal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ravulizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

